Association of the simultaneous administration of Gingko biloba extract and absorption promoting agent with cognitive functio
- Conditions
- Healthy adults
- Registration Number
- JPRN-UMIN000043494
- Lead Sponsor
- Department of Aging Research and Geriatric Medicine IDAC, Tohoku University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 155
Not provided
1) With past history of severe neurological diseases. 2) With critical bleeding incidents. 3) Use of antithrombotic medicine. 4) Severe depression 5) Patients with diabetes mellitus. 6) With severe visual or auditory disability. 7) Individuals with any metal implantation, such as cardiac pacemaker, coronary stent and artificial joint. 8) Claustrophobia. 9) Use of any supplement. 10) Creatinine clearance less than 15ml/min. 11) Patients with gastrointestinal diseases or metabolic diseases. 12) Diagnosed psychiatric disorders. 13) Participants who cannot obtain the informed consent. 14) Allergy to the study materials. 15) Individuals who is not suitable for participating in this study decided by principal investigator.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The primary endpoint of this study is to discover any alteration of cognitive function in healthy adults assessed by Wechsler Memory Scale revised (WMS-R) following 24 weeks administration of GBE/MST.
- Secondary Outcome Measures
Name Time Method